Actinium

Oliver Sartor and Louise Emmett discuss combination therapy approaches with lutetium-PSMA in prostate cancer, focusing on strategies like hormonal therapies, taxanes, DNA repair inhibitors, immunotherapy, and dual isotope treatments. They highlight the ENZA-p trial's promising results, emphasizing the need for rational, well-tolerated combinations tailored to disease stage and patient needs, while managing toxicity profiles.

OncoOne, founded in 2018, focuses on developing tumor-targeted radioimmunotherapy (RIT) using its PreTarg-it platform to treat solid tumors, aiming to reduce side effects. The platform, designed for both therapeutic and diagnostic use, involves a two-step process: first, non-labeled antibodies target the tumor, followed by a small molecule carrying a cytotoxic or diagnostic nucleate. This method minimizes radiation exposure to healthy tissue, with a typical treatment cycle lasting up to 10 days. OncoOne's lead candidate, ON105, targets pancreatic cancer, with plans to expand to other hard-to-treat cancers.